Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ticagrelor whole · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Ticagrelor 90 mg as a whole tablet |
| B | EXPERIMENTAL | Ticagrelor 90 mg tablet crushed and suspended in water |
| C | EXPERIMENTAL | Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach |
| Name | Type | Description |
|---|---|---|
| Ticagrelor 90 mg whole tablet | DRUG | Ticagrelor 90 mg whole tablet administered as a single oral dose |
| Ticagrelor 90 mg tablet crushed | DRUG | Ticagrelor 90 mg crushed and suspended in water |
| Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube | DRUG | Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach |
Inclusion Criteria: * Healthy male and female volunteers aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venepuncture * Have a body mass index between 18 and 30 kg/m2 (inclusive) and weigh at least 50 kg (110 pounds \[lbs\]) and no more than 100 kg (220 lbs). * Provi...
Ticagrelor whole is a small molecule being investigated for use in healthy volunteers to study bioavailability. It is currently in Phase 1 clinical development, with a completed trial that examined how the uptake of ticagrelor into the body differs depending on the method of administration.
Ticagrelor whole is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical research on this small molecule, with a Phase 1 trial focused on bioavailability in healthy volunteers.
Ticagrelor whole is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied for its bioavailability in healthy volunteers. One Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
Ticagrelor whole has one completed clinical trial, NCT01887626, titled "Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration." This Phase 1 trial enrolled 36 healthy volunteers in the United Kingdom and was controlled but not double-blinded.
Ticagrelor whole is a formulation of ticagrelor, a small molecule. The trial NCT01887626 investigates how the uptake of ticagrelor into the body differs depending on the method of administration, indicating that Ticagrelor whole refers to a specific formulation or administration method being studied.